TD Waterhouse Canada Inc. Acquires 15,024 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

TD Waterhouse Canada Inc. boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 601.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,524 shares of the company's stock after acquiring an additional 15,024 shares during the period. TD Waterhouse Canada Inc.'s holdings in Hims & Hers Health were worth $424,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of HIMS. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Hims & Hers Health by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Hims & Hers Health by 7.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock worth $43,448,000 after acquiring an additional 129,416 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 100,000 shares of Hims & Hers Health stock in a transaction on Friday, January 31st. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $983,271.96. The trade was a 78.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 712,998 shares of company stock valued at $27,992,450. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $0.42 during mid-day trading on Monday, reaching $28.51. The stock had a trading volume of 32,720,529 shares, compared to its average volume of 15,718,007. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of 64.80 and a beta of 1.65. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The business has a fifty day moving average of $33.44 and a 200 day moving average of $31.15.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on HIMS. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target for the company. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Bank of America lifted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research note on Tuesday, March 18th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their target price for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus price target of $38.08.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.